PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting demonstrated responses in patients across multiple solid tumor types with a p53 Y220C... | August 9, 2022
Source: marketscreener.com